Literature DB >> 11208847

Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients.

M Trassard1, V Le Doussal, K Hacène, P Terrier, D Ranchère, L Guillou, M Fiche, F Collin, M O Vilain, G Bertrand, J Jacquemier, X Sastre-Garau, N B Bui, F Bonichon, J M Coindre.   

Abstract

PURPOSE: To identify most significant and therapeutically relevant prognostic factors in adults with localized primary synovial sarcomas (SS) and to confirm the usefulness of the French Federation of Cancer Centers (FNCLCC) grading system, the prognostic impact of which has been already proven in soft tissue sarcomas. PATIENTS AND METHODS: Data on 128 patients with nonmetastatic SS collected from a cooperative database by the FNCLCC Sarcoma Group between 1980 and 1994 were studied retrospectively. Immunohistochemistry was performed at diagnosis in 77 cases (61%). The tumors were classified as biphasic (n = 45), monophasic fibrous (n = 72), and poorly differentiated (n = 10) subtypes. Histologic grade was determined according to the FNCLCC method, and vascular invasion was assessed in every case.
RESULTS: The 5-year disease-specific survival (DSS) rate for this series of patients with localized SS was 62.9% (+/- 9.6% [SD]) with a median follow-up time of 37 months (range, 8 to 141 months). In multivariate analysis, the adverse risk factors associated with decreased DSS were International Union Against Cancer/American Joint Committee on Cancer stage III/IVA disease, male sex, and truncal tumor locations. For metastasis-free survival (MFS), disease stage III/IVA, tumor necrosis, and monophasic subtypes were the major factors associated with a less favorable prognosis. Separately, when not using disease stage, tumor necrosis, and mitotic activity, histologic grade became the most significant prognostic factor for both DSS and MFS. In addition, larger tumors and older patients become associated with a significantly worse prognosis. Independent adverse risk factors for local recurrence-free survival included histologic grade 3 and truncal tumor location.
CONCLUSION: These data confirm that not all SS present the same severe outcome. High-risk patients identified on the basis of these parameters may qualify for an aggressive treatment approach.

Entities:  

Mesh:

Year:  2001        PMID: 11208847     DOI: 10.1200/JCO.2001.19.2.525

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  70 in total

1.  A rare case of synovial sarcoma involving the brachial plexus.

Authors:  Anand Vasant Ghiya; Mrunal Nitin Ketkar; Shilpa Patankar; Sudhir Kothari
Journal:  Indian J Surg Oncol       Date:  2011-06-17

2.  Macroscopic vascular invasion in synovial sarcoma evident on MRI.

Authors:  Y M Tang; S Stuckey; D Lambie; G M Strutton
Journal:  Skeletal Radiol       Date:  2005-08-20       Impact factor: 2.199

3.  Diagnosis of primary esophageal synovial sarcoma by demonstration of t(X;18) translocation: a case report.

Authors:  Catherine Butori; Véronique Hofman; Rita Attias; Jerôme Mouroux; Florence Pedeutour; Paul Hofman
Journal:  Virchows Arch       Date:  2006-06-21       Impact factor: 4.064

4.  An unusual breast mass: primary synovial sarcoma.

Authors:  Victoria J Doyle; Adrian C Bateman; Jeffery M Theaker
Journal:  BMJ Case Rep       Date:  2013-06-19

5.  Primary pulmonary synovial sarcoma: a rare primary pulmonary tumor.

Authors:  Roger Fei Falkenstern-Ge; Martin Kimmich; Andreas Grabner; Heike Horn; Godehard Friedel; German Ott; Martin Kohlhäufl
Journal:  Lung       Date:  2013-10-30       Impact factor: 2.584

6.  Rare case: Monophasic pleuropulmonary synovial sarcoma.

Authors:  Rateesh Sareen; Chandra Lekha Pandey
Journal:  South Asian J Cancer       Date:  2013-07

7.  Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.

Authors:  Ulviye Yalçınkaya; Nesrin Uğraş; Gonca Özgün; Gökhan Ocakoğlu; Adem Deligönül; Sibel Kahraman Çetintaş; Muhammed Sadık Bilgen
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

8.  Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.

Authors:  Susanne V Allander; Peter B Illei; Yidong Chen; Cristina R Antonescu; Mike Bittner; Marc Ladanyi; Paul S Meltzer
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

9.  Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients.

Authors:  Sameer Yaser; Samer Salah; Marwa Al-Shatti; Areej Abu-Sheikha; Ahmad Shehadeh; Iyad Sultan; Ahmad Salem; Maher Sughayer; Shaymaa Al-Loh; Abdelatif Al-Mousa
Journal:  Med Oncol       Date:  2014-04-26       Impact factor: 3.064

10.  Intraneural synovial sarcoma of the median nerve.

Authors:  Angelo B Lipira; Rahul Kasukurthi; Wilson Z Ray; Mark E Pruzansky; Susan E Mackinnon
Journal:  Rare Tumors       Date:  2010-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.